This prospective study enrolled healthcare workers (HCWs) who were nonresponders following at least 5 doses of aluminum-adjuvanted hepatitis B vaccine who received the 2-dose Heplisav-B (HepB-CpG) (Dynavax Technologies Corporation, Emeryville, CA) series. After 2 doses of HepB-CpG, 43/47 (...
Infants in groups at high risk for perinatal and early childhood HBV infections should complete the three-dose hepatitis B vaccine series by age 6 months. When vaccines that do not contain thimerosal as a preservative are not available, these groups should be vaccinated with thimerosal preservative...
A complete hepatitis B vaccine series produces a protective immune responses in over 95% of vaccine recipients. The most commonadverse eventfollowing hepatitis Bvaccinationis pain at theinjection site. The WHO Global Advisory Committee onVaccine Safetyhas reviewed the safety of hepatitis B vaccines and...
Hepatitis B vaccineis increasingly a routine childhoodvaccinationin many countries and is part of the WHO GAVI recommendations for highly endemic countries. The three-dose series can be started immediately at birth, with a schedule of 0, 1, and 6 months. Alternatively, doses can be given at ...
Protect yourself with HEPLISAV-B®, a 2-dose hepatitis B vaccine for adults. Learn about Hep-B vaccination and where to find HEPLISAV-B® at a pharmacy near you
Abstract Importance Receipt of hepatitis B virus vaccine is important to prevent infection. However, adherence to the hepatitis B vaccine series among adults at risk of infection has been low. Objective To assess whether recipients of a 2-dose hepatitis B vaccine with cytosine phosphoguanine adjuvant...
According to the Centers for Disease Control, Hepatitis B is a vaccine-preventable liver infection caused by the hepatitis B virus (HBV). Hepatitis B is spread when blood, semen, or other body fluids from a person infected with the virus enters the body of someone who is not infected. This...
A total of 236 individuals were evaluated in this study and only 53% or 124 persons developed protective levels of antibody to hepatitis B surface antigen following a complete vaccine series. In one hospital, 30% of the vaccine recipients developed antibody but not to a protective level. ...
Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. Each of a series of three B (B) inoculations was given to 48 second-year medical students on the 3rd day of a 3-day examination series to study the effect ... R Glaser,JK Kiecolt-Glaser,RH Bonneau,.....
HBIG: hepatis B immune globulin * The final dose in the vaccine series should be administrated before age 24 weeks ** These infants should be tasted for antibody to HBsAG (anti-HBs) and HBsAg at age 9 to 12 months or 1 to 2 months after the last dose of the hepatitis B vaccine. ...